Substituted aminoquinolones as DGKalpha inhibitors for immune activation

Patent metadata

Field	Value
Publication number	US-11998539-B2
Application number	US-202218072490-A
Country	US
Kind code	B2
Filing date	Nov 30, 2022
Priority date	Nov 28, 2019
Publication date	Jun 4, 2024
Grant date	Jun 4, 2024

Abstract

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

First claim

The invention claimed is:

1. A compound having the structure:

or a hydrate or solvate thereof, or a pharmaceutically acceptable salt of any of the foregoing.

2. The compound of claim 1 , wherein the compound is

3. A pharmaceutical composition comprising a compound of claim 1 , or a hydrate or solvate thereof, or a pharmaceutically acceptable salt of any of the foregoing, and at least one pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising a compound of claim 2 and at least one pharmaceutically acceptable excipient.

5. A method of treating or preventing a disease or condition associated with dysregulated immune responses or aberrant DGKα signaling in a mammal, comprising administering an effective amount of a compound of claim 1 , or a hydrate or solvate thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the mammal.

6. The method of claim 5 , wherein the mammal is a human.

7. The method of claim 5 , wherein the disease is cancer.

8. The method of claim 5 , wherein the compound or pharmaceutically acceptable salt thereof exercises its effect through T-cell activation.

9. The method of claim 5 , wherein the disease is non-small cell lung cancer (NSCLC), gastric cancer, gastric adenocarcinoma, esophageal adenocarcinoma, melanoma, or colorectal cancer.

10. The method of claim 5 , wherein the disease is non-small cell lung cancer.

11. The method of claim 5 , wherein the disease is gastric cancer.

12. The method of claim 5 , wherein the disease is gastric adenocarcinoma or esophageal adenocarcinoma.

13. The method of claim 5 , wherein the disease is melanoma.

14. The method of claim 5 , wherein the disease is colorectal cancer.

15. A method of treating or preventing a disease or condition associated with dysregulated immune responses or aberrant DGKα signaling in a mammal, comprising administering an effective amount of 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, to the mammal.

16. The method of claim 15 , wherein the mammal is a human.

17. The method of claim 15 , wherein the disease is cancer.

18. The method of claim 15 , wherein 6-fluoro-1-methyl-4-[4- (5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide exercises its effect through T-cell activation.

19. The method of claim 15 , wherein the disease is non-small cell lung cancer (NSCLC), gastric cancer, gastric adenocarcinoma, esophageal adenocarcinoma, melanoma, or colorectal cancer.

20. The method of claim 15 , wherein the disease is non-small cell lung cancer.

21. The method of claim 15 , wherein the disease is gastric cancer.

22. The method of claim 15 , wherein the disease is gastric adenocarcinoma or esophageal adenocarcinoma.

23. The method of claim 15 , wherein the disease is melanoma.

24. The method of claim 15 , wherein the disease is colorectal cancer.

Assignees

• Bayer Ag
• Bayer Pharma AG
• Deutsches Krebsforsch

Inventors

• Schmees Norbert
• Wortmann Lars
• Kirchhoff Dennis
• Nguyen Thi Thanh Uyen
• Werbeck Nicolas
• Bömer Ulf
• Petersen Kirstin
• Kober Christina
• Lechner Christian
• Kosemund Dirk
• Offringa Rienk
• Grees Mareike
• Bader Benjamin

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/4709 Primary

  Non-condensed quinolines and containing further heterocyclic rings · CPC title